TD Cowen Maintains Buy on NeoGenomics, Raises Price Target to $14

Benzinga Newsdesk www.benzinga.com Positive 74.7%

Neg 0% Neu 0% Pos 74.7%

TD Cowen analyst Dan Brennan maintains NeoGenomics (NASDAQ:NEO) with a Buy and raises the price target from $13 to $14.

Comments

No comments yet. Be the first!